Rein Net Income Per Share from 2010 to 2025
| RNTX Stock | 1.14 0.10 8.06% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -3.5 K | Current Value -3.3 K | Quarterly Volatility 1.2 K |
Check Rein Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rein Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 66.2 K, Selling General Administrative of 14.6 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.0E-4. Rein financial statements analysis is a perfect complement when working with Rein Therapeutics Valuation or Volatility modules.
Rein | Net Income Per Share | Build AI portfolio with Rein Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Rein Stock Analysis
When running Rein Therapeutics' price analysis, check to measure Rein Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rein Therapeutics is operating at the current time. Most of Rein Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rein Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rein Therapeutics' price. Additionally, you may evaluate how the addition of Rein Therapeutics to your portfolios can decrease your overall portfolio volatility.